DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Azilsartan
Azilsartan
Unique Binding Behavior of the Recently Approved Angiotensin II Receptor Blocker Azilsartan Compared with That of Candesartan
Annexes to the EMA Annual Report 2009
Edarbi Generic Name: Azilsartan Manufacturer1
Efficacy and Safety of Azilsartan Medoxomil, an Angiotensin Receptor
Azilsartan, but Not Candesartan Improves Left Ventricular Diastolic Function in Patients with Hypertension and Heart Failure*
Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores
ACE2 As a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System
Committee to Evaluate Drugs (CED) Recommendations and Reasons
Azilsartan: Current Evidence and Perspectives in Management of Hypertension
Angiotensin II Receptor Antagonists (Arbs), Renin
Package Leaflet: Information for the User Edarbi 20 Mg Tablets Edarbi 40 Mg Tablets Edarbi 80 Mg Tablets Azilsartan Medoxomil Re
Rational Design and Synthesis of AT1R Antagonists
AHRQ%Systematic%Review%Surveillance% Program%
Possible Benefits of Azilsartan Compared with Other Angiotensin II
Angiotensin II Receptor Blockers -August 2014
Angiotensin Receptor Blockers (Arbs)
Angiotensin Ii Receptor Antagonist (Arb) Dosing: Tool for Switching Between Agents in Canada
Efficacy of Azilsartan and Telmisartan in Patients with Type 2 Diabetes and Hypertension
Top View
ACE2 As a Potential Therapeutic Target for Pandemic COVID-19 Cite This: RSC Adv., 2020, 10,39808 Bhaswati Chatterjee *A and Suman S
ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
Valsartan Recall Angiotensin II Receptor Blockers (Arbs) Equivalent Dosing
EARLY Treatment with Azilsartan Compared to ACE-Inhibitors in Anti
First-Line Combination Therapy Versus First-Line Monotherapy for Primary Hypertension (Review)
Azilsartan Compared to ACE Inhibitors in Anti-Hypertensive Therapy: One-Year Outcomes of the Observational EARLY Registry Anselm K
Suffolk Drug & Therapeutics Group
Antihypertensive Effect of Azilsartan Versus Olmesartan in Patients with Essential Hypertension: a Meta-Analysis
Nova Scotia Formulary Updates Nova Scotia Formulary Updates New Benefit Status New Benefit Status
List of Selected Drugs
A Two-Tiered Unsupervised Clustering Approach for Drug Repositioning
What Can We Expect from the Binding Characteristics of Azilsartan, a Newly Available Angiotensin II Blocker, in Hypertension?
Cdec Final Recommendation
Edarbi, INN-Azilsartan Medoxomil
Renin-Angiotensin System Blockade and Pleiotropic Cardiovascular Effects: the Novel Angiotensin Receptor Blocker Azilsartan
Edarbi, INN-Azilsartan Medoxomil
The Renin-Angiotensin Receptor Blocker Azilsartan Medoxomil
Edarbi (Azilsartan Medoxomil) Tablets Impairment
Azilsartan As a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: a Review Study
Angiotensin Receptor Blocker (ARB) Antihypertensive Dose Comparison
The Renin-Angiotensin Receptor Blocker Azilsartan Medoxomil
Angiotensin II Receptor Antagonists) Are All Indicated for Adults with Hypertension